Stoke Therapeutics Announces Completion Of Enrollment Of 162 Patients Into The Phase 3 Emperor Study Of Zorevunersen, An Investigational Medicine For The Treatment Of Dravet Syndrome

Stoke Therapeutics Inc NASDAQ:STOK:

• STOKE THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT OF 162 PATIENTS INTO THE PHASE 3 EMPEROR STUDY OF ZOREVUNERSEN, AN INVESTIGATIONAL MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME

• STOKE THERAPEUTICS - PLANS TO INITIATE ROLLING U.S. NDA SUBMISSION TO FDA IN Q1 2027

• STOKE THERAPEUTICS - PHASE 3 DATA READOUT ANTICIPATED IN Q3 2027, TO COMPLETE NDA SUBMISSION IN H2 2027

• STOKE THERAPEUTICS - NO PATIENTS HAVE DISCONTINUED TREATMENT IN PHASE 3 EMPEROR STUDY